UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 2)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 15, 2019
PDS Biotechnology Corporation
(Exact name of registrant as specified in its charter)
| Delaware | 001-37568 | 26-4231384 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
300 Connell Drive, Suite 4000 Berkeley Heights, NJ | | 07922 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code (800) 208-3343
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.00033 per share | PDSB | Nasdaq Capital Market |
Explanatory Note
As disclosed under the section entitled “Introductory Note” on the Current Report on Form 8-K (the “Original Form 8-K”) filed with the Securities and Exchange Commission on March 18, 2019, by PDS Biotechnology Corporation, a Delaware corporation (the “Company”), on March 15, 2019, the Company consummated the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, as amended, dated as of November 23, 2018 (the “Merger Agreement”), by and among Edge Therapeutics, Inc., a Delaware corporation (“Edge”), Echos Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and privately held PDS Biotechnology Corporation, a Delaware corporation (“Private PDS”), pursuant to which Merger Sub merged with and into Private PDS, with Private PDS surviving as a wholly-owned subsidiary of Edge (the “Merger”). Pursuant to the Merger Agreement, Edge changed its name to PDS Biotechnology Corporation (the “Combined Company”) and Private PDS changed its name to PDS Operating Corporation. This Amendment No. 2 to the Current Report on Form 8-K amends the Original Form 8-K, as amended by Amendment No. 1, to provide the unaudited pro forma condensed combined financial statements of the Combined Company as required by Item 9.01(b) of Form 8-K. Such financial information was excluded from the Original Form 8-K, as amended by Amendment No. 1, in reliance on the instructions to such Items.
| Item 9.01. | Financial Statements and Exhibits. |
(b) Pro Forma Financial Information.
The unaudited pro forma condensed combined financial statements for the year ended December 31, 2018, and notes related thereto, of the Combined Company are filed herewith as Exhibit 99.3 and are incorporated herein by reference.
(d) Exhibits.
Exhibit | | Description of Document | Incorporated by Reference |
Schedule/ Form | File Number | Exhibits | Filing Date |
| | | | | | | |
| 2.1 | | | Form 8-K | 001-37568 | Exhibit 2.1 | November 26, 2018 |
| | | | | | | |
| 2.2 | | | Form 8-K | 001-37568 | Exhibit 2.1 | January 30, 2019 |
| | | | | | | |
| 3.1 | | | Form 8-K | 001-37568 | Exhibit 3.1 | March 18, 2019 |
| | | | | | | |
| 3.2 | | | Form 8-K | 001-37568 | Exhibit 3.2 | March 18, 2019 |
| | | | | | | |
| 23.1 | | | Form 8-K | 001-37568 | Exhibit 23.1 | April 30, 2019 |
| | | | | | | |
| 99.1 | | | Form 8-K | 001-37568 | Exhibit 99.1 | March 18, 2019 |
| | | | | | | |
| 99.2 | | | Form 8-K | 001-37568 | Exhibit 99.2 | April 30, 2019 |
| | | | | | | |
| 99.3* | | | | | | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | PDS Biotechnology Corporation |
| Dated: May 24, 2019 | | |
| | By: | |
| | Name: | Frank Bedu-Addo |
| | Title: | President and Chief Executive Officer |
